Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gen1160
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEN1160 is an antibody-drug conjugate (ADC) designed to target CD70, a protein aberrantly overexpressed in multiple hematologic malignancies and carcinomas, with limited normal tissue expression. The ADC consists of an anti-CD70 monoclonal antibody conjugated to a cytotoxic payload that inhibits DNA topoisomerase I (TOP1), enabling targeted delivery to CD70-expressing cancer cells. Its mechanism aims to induce selective cancer cell killing and minimize off-target toxicity compared to traditional chemotherapies. GEN1160 is undergoing Phase 1/2 clinical trials for advanced solid tumors and hematologic malignancies, including metastatic renal cell carcinoma, non-Hodgkin lymphoma (notably diffuse large B-cell lymphoma and mantle-cell lymphoma), and nasopharyngeal carcinoma[1][2][3][5][6][7][8][9][10]. The primary route of administration is intravenous infusion[9]. Developers include Genmab, a biotechnology company; ProfoundBio is listed as the sponsor for several trials[2][5].
- Brand names
- GEN1160GEN-1160GEN 1160
- Other names
- GEN1160GEN-1160GEN 1160PRO1160PRO-1160PRO 1160
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on gen1160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gen1160.